Year archive

Novartis AG — 2017 filings

All 74 regulatory filings released by Novartis AG (NOVN) in 2017, sourced directly from the official regulator.

74 Filings

2017 Period

2017 filings (74)

Filing	Released	Lang
M&A Activity 2017 M&A Activity	2017-12-21	English
SC TO-T/A Filing Merger & Acquisition	2017-12-21	English
FORM 6-K Board/Management Information	2017-12-20	English
SC 13G/A Major Shareholding Notification	2017-12-19	English
PRIMARY DOCUMENT Director's Dealing	2017-12-15	English
Novartis announces Oncology head to retire Board/Management Information	2017-12-15	English
4 Director's Dealing	2017-12-14	English
SC TO-T Filing Merger & Acquisition	2017-12-07	English
SC TO-C Filing M&A Activity	2017-11-24	English
PRIMARY DOCUMENT Director's Dealing	2017-11-17	English
FORM 6-K Regulatory Filings	2017-11-14	English
FORM 6-K Regulatory Filings	2017-11-14	English
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants Earnings Release Q4 2017	2017-11-13	English
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event Regulatory Filings	2017-11-13	English
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Regulatory Filings	2017-11-13	English
FORM 6-K Capital/Financing Update	2017-10-30	English
SC TO-C Filing M&A Activity	2017-10-30	English
6-K Regulatory Filings	2017-10-24	English
Novartis delivered growth on top and bottom line in all divisions in Q3 Earnings Release Q3 2017	2017-10-24	English
FORM 6-K Board/Management Information	2017-10-10	English
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. Board/Management Information	2017-09-04	English
FORM 6-K Regulatory Filings	2017-08-30	English
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice Regulatory Filings	2017-08-30	English
FORM 6-K Regulatory Filings	2017-08-28	English
FORM 6-K Regulatory Filings	2017-08-28	English
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned Regulatory Filings	2017-08-28	English
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk Earnings Release Q3 2017	2017-08-28	English
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk Earnings Release Q3 2017	2017-08-28	English
PRIMARY DOCUMENT Director's Dealing	2017-08-23	English
6-K Regulatory Filings	2017-07-18	English
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products Interim / Quarterly Report Q2 2017	2017-07-18	English
FORM 6-K Regulatory Filings	2017-07-13	English
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL Legal Proceedings Report	2017-07-13	English
FORM 4 SUBMISSION Director's Dealing	2017-07-06	English
FORM 3 SUBMISSION Director's Dealing	2017-06-29	English
FORM 6-K Regulatory Filings	2017-06-22	English
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack Earnings Release Q2 2017	2017-06-22	English
FORM 4 SUBMISSION Director's Dealing	2017-06-20	English
FORM 6-K Regulatory Filings	2017-06-20	English
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval Regulatory Filings	2017-06-20	English
FORM 4 SUBMISSION Director's Dealing	2017-06-12	English
FORM 4 SUBMISSION Director's Dealing	2017-06-08	English
FORM 4 SUBMISSION Director's Dealing	2017-06-06	English
FORM 4 SUBMISSION Director's Dealing	2017-06-02	English
SD Regulatory Filings	2017-05-31	English
FORM 6-K Regulatory Filings	2017-05-31	English
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018 Earnings Release Q1 2017	2017-05-31	English
FORM 4 SUBMISSION Director's Dealing	2017-05-30	English
FORM 4 SUBMISSION Director's Dealing	2017-05-25	English
FORM 4 SUBMISSION Director's Dealing	2017-05-23	English
FORM 4 SUBMISSION Director's Dealing	2017-05-18	English
FORM 3 SUBMISSION Director's Dealing	2017-05-09	English
Regulatory Filings 2017 Regulatory Filings	2017-05-03	English
FORM 4 SUBMISSION Director's Dealing	2017-05-02	English
6-K Regulatory Filings	2017-04-25	English
Regulatory Filings 2017 Regulatory Filings	2017-04-20	English
FORM 6-K Regulatory Filings	2017-03-30	English
Regulatory Filings 2017 Regulatory Filings	2017-03-27	English
Regulatory Filings 2017 Regulatory Filings	2017-03-23	English
FORM 6-K Regulatory Filings	2017-03-22	English
FORM 4 SUBMISSION Director's Dealing	2017-03-18	English
FORM 3 SUBMISSION Director's Dealing	2017-03-18	English
S-8 POS Regulatory Filings	2017-03-15	English
FORM 6-K Regulatory Filings	2017-03-14	English
FORM 4 SUBMISSION Director's Dealing	2017-03-07	English
POST-EFFECTIVE AMENDMENT NO.2 Capital/Financing Update	2017-02-17	English
PROSPECTUS SUPPLEMENT Capital/Financing Update	2017-02-15	English
FWP Capital/Financing Update	2017-02-14	English
PRELIMINARY PROSPECTUS SUPPLEMENT Capital/Financing Update	2017-02-14	English
6-K Regulatory Filings	2017-02-14	English
IRANNOTICE Regulatory Filings	2017-01-25	English
20-F Annual Report FY 2016	2017-01-25	English
6-K Regulatory Filings	2017-01-25	English
6-K Regulatory Filings	2017-01-25	English

Filings by year

2026 10 filings
2025 43 filings
2024 59 filings
2023 33 filings
2022 18 filings
2021 23 filings
2020 49 filings
2019 66 filings
2018 109 filings
2017 74 filings
2016 25 filings
2015 38 filings
2014 44 filings
2013 31 filings
2012 85 filings
2011 138 filings
2010 116 filings
2009 109 filings